Central retinal vein occlusion
Conditions
Interventions
bevasizumab ranibizumab 6M 1.25mg(0.05ml) 0.5mg(0.05ml) one or more times(PRN)
Sponsors
Tsukazaki hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: eyes with CRVO
Exclusion criteria
Exclusion criteria: excluding other retinal diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| venous tortuosity before therapy and retinal blood flow before and after therapy | — |
Countries
Japan
Contacts
Public ContactDaisuke Nagasato
Tsukazaki hospital Ophthalmology
Outcome results
None listed